Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid

The level of histone deacetylation is closely associated with the genesis and development of tumors, but the antitumor effect and mechanism of the class I histone deacetylase inhibitor (HDACI) valproate acid sodium (VPA) on hepatocellular carcinoma cells has not been clearly demonstrated. In the present study, the antitumor effect and mechanism of VPA were measured in vitro. Firstly, it was found that, as an HDAC inhibitor, VPA could inhibit HDAC activity and HDAC1 gene expression in hepatocellular carcinoma cells and, as a result, an inhibition of cell proliferation was detected by MTT assay. Subsequently, the cell cycle and cell apoptosis profiles were analyzed using flow cytometry (FCM). The expression of the mRNA and protein of cyclins A, D1 and E and P21Waf/cip1 was measured by reverse transcription-polymerase chain reaction and FCM analysis to determine the molecular mechanism of VPA-induced cell cycle arrest. The activity and mRNA and protein expression of caspases 3, 8 and 9 were detected to determine the apoptotic pathway. Caspase expression was blocked by caspase inhibitors in order to observe whether the intrinsic or extrinsic pathway contributed to HepG2 cell apoptosis. The results revealed that the mRNA and protein expression of cyclins A and D1 was downregulated while the expression of P21Waf/cip1 was upregulated by VPA. The expression of cyclin E was only slightly affected by VPA. The mRNA and protein expression and activity of caspases 3 and 9 were upregulated by VPA. By contrast, inhibitors of caspases 3 and 9 could reverse cell apoptosis and there was no notable change in caspase 8 expression in any of these experiments. The intrinsic apoptosis pathway, but not the death receptor pathway, contributed to the induction of apoptosis in hepatocellular carcinoma cells. Furthermore, VPA could inhibit the proliferation of hepatocellular carcinoma cells by inducing G1 phase arrest and cell apoptosis. These effects were attributed to the change in the caspase level.

[1]  T. Stearns,et al.  Mechanism limiting centrosome duplication to once per cell cycle , 2006, Nature.

[2]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[3]  Hui Yang,et al.  Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. , 2005, Leukemia research.

[4]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[5]  H. J. Cruft,et al.  Abnormal Properties of Histones from Malignant Cells , 1954, Nature.

[6]  Qi Zhou,et al.  Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. , 2003, World journal of gastroenterology.

[7]  D. Faller,et al.  A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. , 2005, Current pharmaceutical design.

[8]  G. Braunstein,et al.  Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo , 2006, Clinical Cancer Research.

[9]  Jun Lu,et al.  HDAC inhibitors: a potential new category of anti-tumor agents. , 2007, Cellular & molecular immunology.

[10]  Junying Yuan,et al.  Caspases in apoptosis and beyond , 2008, Oncogene.

[11]  B. Turner,et al.  Cellular Memory and the Histone Code , 2002, Cell.

[12]  J. S. Rao,et al.  Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. , 2005, International journal of oncology.

[13]  H. S. Kim,et al.  Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. , 2000, Cancer research.

[14]  D. Mottet,et al.  Histone deacetylases: target enzymes for cancer therapy , 2007, Clinical & Experimental Metastasis.

[15]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[16]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[17]  M. Bialer,et al.  The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors , 2004, Epilepsia.

[18]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[19]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[20]  Min Kyoung Kim,et al.  Cell cycle arrest and apoptotic induction in LNCaP cells by MCS‐C2, novel cyclin‐dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway , 2006, Cancer science.

[21]  J. Buolamwini.  Cell cycle molecular targets in novel anticancer drug discovery. , 2000, Current pharmaceutical design.

[22]  Minshan Chen,et al.  High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[23]  O. Bosco,et al.  Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  Seamus J. Martin,et al.  Caspase activation cascades in apoptosis. , 2008, Biochemical Society transactions.